$TDOC

Teladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, Mr. David B. Snow, Jr. notified Teladoc Health, Inc. (the “Company”) of his intention to retire from th

Simply Wall St says Teladoc Health (TDOC) appointed Mark V. Anquillare to its board and updated 2026 guidance after recent quarterly results. The stock last traded at $6.81, down 26.62% over 30 days and 95.10% over five years. The article cites a $15.00 fair value estimate and discusses cash flow and BetterHelp’s insurance shift.

Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, down 4% year over year, with BetterHelp revenue $212.6 million, down 11% due to a faster shift from cash pay to insurance. Adjusted EBITDA was $65.7 million. Full-year 2026 guidance: revenue $2.36B to $2.45B and adjusted EBITDA $271M to $303M. CEO Charles Divita said insurance demand outpaced provider capacity.

Levi & Korsinsky said it is investigating Teladoc Health (NYSE: TDOC) after the company reported Q2 2026 revenue of $606.9 million, below consensus of $615 million to $628 million, and cut full-year 2026 revenue guidance to $2.36 billion to $2.45 billion. The notice cites prior guidance changes and comments about BetterHelp cash pay user declines and insurance capacity.

Teladoc (TDOC) shares fell more than 28% after earnings, as the shift toward insurance-covered BetterHelp services is said to be creating a gap between demand and provider capacity. The article cites TDOC’s P/S near 0.48, Q2 cash of about $774M, and expected FY free cash flow of $130M to $170M. Analyst targets range from $5.50 to $11.

Teladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors NEW YORK, August 3, 2026 -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anqu

Teladoc Health (NYSE: TDOC) said it appointed Mark V. Anquillare to its board of directors. He previously served as president and COO of Verisk Analytics and will sit on the Audit and Compensation committees, according to the company. The announcement cites his experience as Verisk CFO and COO and his current board role at Guidewire Software.

Teladoc Health reported Q2 results with revenue of $606.93M and a net loss of $38.91M, and issued guidance expecting continued losses in Q3 and full-year 2026. The company lowered 2026 revenue guidance to $2.362B-$2.447B and net loss to $181M-$136M, citing pressure from BetterHelp as users shift to insurance-covered care.

Teladoc Health, owner of BetterHelp, said demand for insurance-covered therapy is outpacing its ability to credential therapists. In Q2, cash-pay therapy revenue fell faster than insurance revenue rose. BetterHelp revenue fell 12% YoY to $213M; insurance revenue was $22M. Shares dropped about 27% after results.

Teladoc (TDOC) shares fell after the company reported Q2 results that did not meet expectations. The article says analysts remain bullish, with a consensus “Moderate Buy” rating and a mean price target around $8, implying more than 22% upside from the current level.